<DOC>
	<DOCNO>NCT00165880</DOCNO>
	<brief_summary>The overall purpose study compare efficacy , safety tolerability indisulam combination capecitabine ( IC ) versus capecitabine ( C ) monotherapy patient metastatic breast cancer previously treat anthracycline taxane .</brief_summary>
	<brief_title>An Open-label , Randomized , Phase II Study Efficacy Safety Indisulam ( E7070 ) Combination With Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Ambulant female patient metastatic breast cancer treat previously anthracycline taxane enrol . Patients must fulfill follow criterion include study : Histologically cytologically confirm breast cancer least one metastatic unidimensionally measurable lesion accord RECIST criterion ( follow qualify measurable lesion : bone , leptomeningeal disease , ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonis , abdominal mass confirm followed imaging technique , cystic lesion ) . Prior treatment anthracycline taxane . All previous treatment ( include surgery radiotherapy ) must complete least 4 week prior study entry acute toxicity must resolve . Age &gt; = 18 year . Karnofsky performance status &gt; = 70 % . Written inform consent participate study . Patients follow characteristic include study : Previously receive great two prior chemotherapy regimens metastatic breast cancer . Previously receive great three prior chemotherapy regimen total ( include neoadjuvant adjuvant regimen ) breast cancer . Primary diagnosis inflammatory breast cancer , confirm histology cytology . Untreated brain metastasis ( patient treat CNS metastasis must asymptomatic radiologically stable 3 month prior entry ) . Patients must clinical symptom brain metastasis must take corticosteroid treatment brain metastasis . Patients must leptomeningeal metastasis . Concurrent previous malignancy different tumor type within five year start study except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia . Any following laboratory parameter : 1. hemoglobin &lt; 10 g/dl ; 2. neutrophil &lt; 1.5 x 109/L ; 3. platelet &lt; 100 x 109/L ; 4. serum bilirubin &gt; 25 Âµmol/l ( 1.5 mg/dl ) ; 5. liver parameter &gt; 2.5 x upper normal limit ( ULN ) ( &gt; 5 x upper normal limit presence hepatic metastasis ) ; 6. serum creatinine &gt; 1.5 x ULN ; 7. serum calcium ( correct albumin ) &gt; =11.5 mg/dl . Uncontrolled infection . Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start . Malabsorption syndrome condition may affect drug absorption . History hypersensitivity sulfonamide . Prior severe unexpected reaction fluoropyrimidine therapy ( may explain dihydropyrimidine dehydrogenase deficiency hypersensitivity 5fluorouracil ) . Any treatment investigational drug within 30 day start study . Pregnancy lactation ( woman childbearing potential must negative pregnancy test inclusion study ; postmenopausal woman must amenorrheic least 12 month ) . Fertile patient must use adequate contraceptive protection . History alcoholism , drug addiction , psychiatric psychological condition , opinion investigator , would impair study compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>